Medicina
Departamento
Harvard Medical School
Boston, Estados UnidosPublicaciones en colaboración con investigadores/as de Harvard Medical School (190)
2024
-
Clinical Presentation and Outcomes of Patients with Cancer-Associated Isolated Distal Deep Vein Thrombosis
Journal of Clinical Oncology, Vol. 42, Núm. 5, pp. 529-537
-
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
Nature Medicine, Vol. 30, Núm. 1, pp. 271-278
-
Early versus delayed coronary angiography in patients with out-of-hospital cardiac arrest and no ST-segment elevation: a systematic review and meta-analysis of randomized controlled trials
Clinical Research in Cardiology, Vol. 113, Núm. 4, pp. 561-569
-
Efficacy and Safety of Single-inhaler Triple Therapy Containing Dual Bronchodilator With Corticosteroids Compared to Monotherapy, Dual Therapy, or Open Triple Therapy in Moderate/Severe COPD: A Systematic Literature Review
Archivos de Bronconeumologia, Vol. 60, Núm. 1, pp. 55-58
-
Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)
ESMO Open, Vol. 9, Núm. 3
-
Slaying the “Troll of Transplantation”—new frontiers in cytomegalovirus management: A report from the CMV International Symposium 2023
Transplant Infectious Disease, Vol. 26, Núm. 1
-
Statin use and mortality in patients with deep vein thrombosis. Data from the RIETE Registry
Thrombosis Research, Vol. 236, pp. 88-96
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 7, pp. 1370-1375
-
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 7, pp. 1376-1382
-
Ambulatory cancer patients: who should definitely receive antithrombotic prophylaxis and who should never receive
Internal and Emergency Medicine, Vol. 18, Núm. 6, pp. 1619-1634
-
Assessment of a Genomic Assay in Patients with ERBB2 -Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy with or Without Pertuzumab
JAMA Oncology, Vol. 9, Núm. 6, pp. 841-846
-
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer
Annals of Oncology, Vol. 34, Núm. 9, pp. 783-795
-
Biolimus-eluting vs. other limus-eluting stents in NSTE-ACS: A pooled analysis of GLASSY and TWILIGHT
International Journal of Cardiology, Vol. 383, pp. 24-32
-
Clinically Driven Revascularization in High-Risk Patients Treated With Ticagrelor Monotherapy After PCI: Insights from the Randomized TWILIGHT Trial
American Journal of Cardiology, Vol. 208, pp. 16-24
-
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial
The Lancet Respiratory Medicine, Vol. 11, Núm. 1, pp. 74-86
-
Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention
JACC: Cardiovascular Interventions, Vol. 16, Núm. 20, pp. 2514-2524
-
EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma
Annals of Oncology
-
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up
Annals of Oncology, Vol. 34, Núm. 3, pp. 289-299
-
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Nature Medicine, Vol. 29, Núm. 9, pp. 2259-2267